Trial Profile
An Open-Label Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of AN2728 Ointment in Adolescents With Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 May 2020
Price :
$35
*
At a glance
- Drugs Crisaborole (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Anacor Pharmaceuticals
- 20 May 2020 Results (n=244) assessing systemic exposure parameters of crisaborole with ointment dose and identifing covariates that impact the PK parameters of crisaborole in healthy participants and in patients with AD or psoriasis in 6 studies (C3291010, AN2728-PS-104, NCT01258088; C3291019, AN2728-TQT-108; C3291009, AN2728-PK-101; C3291007, AN27208-AD-203, NCT01652885; C3291006, AN2728-AD-102 & C3291012, AN2728-PSR-106), published in the Journal of Clinical Pharmacology.
- 28 Feb 2014 New trial record
- 27 Feb 2014 Anacor Pharmaceuticals originally reported the results of this study on 10 December 2012, according to a company media release.